Proteome Sciences plc (PRM) · 2026-09-16

Interim Results H1 2026

Proteome Sciences reported a 35% narrower first-half loss as TMT revenue rose, while services revenue fell; management expects significant full-year services growth.

Proteome Sciences plc (PRM) · 2026-09-16

Appointment of Non-Executive Director

Proteome Sciences has appointed Helen Spice FCA as an independent non-executive director with immediate effect. Spice was chief financial officer of KPMG International from 2008 to 2015, adding senior finance experience to the board.

Proteome Sciences plc (PRM) · 2026-06-22

Target engagement/chemoproteomics contract

Proteome Sciences has won a further significant clinical contract in its chemoproteomics platform. It expects the deal to lead to a new clinical trial programme later in 2026.

Proteome Sciences plc (PRM) · 2026-06-01

Directorate Changes

Proteome Sciences plc Chief Scientific Officer Dr Ian Pike stepped down from his executive role on 31 May 2026. He transitioned to a Non-Executive Director position and will provide consultancy services to maintain continuity.